Real-world Clinical Outcomes Among Patients With Type 2 Diabetes Receiving Canagliflozin at a Specialty Diabetes Clinic: Subgroup Analysis by Baseline HbA 1c and Age

• Published in: Clinical therapeutics Vol. 39; no. 6; pp. 1123 - 1131
• Main Authors: Johnson, June Felice, Parsa, Rahul, Bailey, Robert A
• Format: Journal Article
• Language: English
• Published: United States 01.06.2017
• Subjects: Adult; Aged; Blood Pressure - drug effects; Body Weight - drug effects; Canagliflozin - therapeutic use; Diabetes Mellitus, Type 2 - blood; Diabetes Mellitus, Type 2 - drug therapy; Diabetes Mellitus, Type 2 - physiopathology; Female; Glycated Hemoglobin A - analysis; Humans; Hypoglycemic Agents - therapeutic use; Male; Middle Aged; Sodium-Glucose Transporter 2 - antagonists & inhibitors; Treatment Outcome; effectiveness; type 2 diabetes mellitus; real-world evidence; sodium glucose co-transporter 2 inhibitor; canagliflozin
• ISSN: 0149-2918; 1879-114X
• DOI: 10.1016/j.clinthera.2017.04.006

Canagliflozin, a sodium glucose co-transporter 2 inhibitor developed for the treatment of type 2 diabetes mellitus (T2DM), has demonstrated effectiveness in patients with T2DM receiving care at a specialty diabetes clinic. We report the outcomes in these patients in subgroups classified by baseline hemoglobin A (HbA ) and age. This subgroup analysis was based on a review of data from the electronic health records of adults with T2DM who were prescribed canagliflozin at a specialty diabetes clinic and who returned for ≥1 follow-up office visit. Mean changes from baseline to the first and second follow-up office visits in HbA , body weight, and systolic and diastolic blood pressure (BP) were calculated in each subgroup classified by baseline HbA (≥7.0%, ≥8.0%, and >9.0%) and age (<65 and ≥65 years). Of the 462 patients included in the study, 430, 305, and 169 patients had baseline HbA ≥7.0%, ≥8.0%, and >9.0%, respectively; 396 and 66 patients were aged <65 and ≥65 years, respectively. With canagliflozin use, patients across subgroups classified by baseline HbA and age experienced clinically and statistically significant reductions from baseline in HbA , body weight, and systolic BP that were sustained over 2 office visits; diastolic BP was also reduced across baseline HbA and age subgroups. Greater reductions in HbA were seen among the canagliflozin-treated patients with higher baseline HbA and among younger versus older patients. These findings from clinical practice demonstrate real-world effectiveness of canagliflozin in lowering HbA , body weight, and systolic BP among patients with T2DM, regardless of baseline HbA levels or age.